| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.3B | ¥1.0B | +36.5% |
| Operating Income | ¥-0.8B | ¥-0.8B | +1.2% |
| Ordinary Income | ¥-0.9B | ¥-0.8B | -6.2% |
| Net Income | ¥-0.9B | ¥-0.8B | -12.2% |
| ROE | -17.3% | -21.5% | - |
FY2026 Q2 results show revenue of 1.3B yen (YoY +36.5%), operating loss of 0.8B yen (YoY improvement of +1.2%), ordinary loss of 0.9B yen (YoY deterioration of -6.2%), and net loss of 0.9B yen (YoY deterioration of -12.2%). Despite significant top-line growth of 36.5%, the company remains in operating loss territory with an operating margin of -59.7%, improving from approximately -82.7% in the prior year period, marking an improvement of roughly 23 percentage points. Gross profit margin stands healthy at 53.6%, but SG&A expenses of 1.5B yen, representing 113.3% of revenue, continue to drive operating losses. Operating cash flow recorded negative 1.8B yen with operating CF to net income ratio of 2.03x, indicating cash outflow exceeds accounting losses primarily due to working capital deterioration, particularly accounts receivable increasing 92.9% YoY. Total assets reached 18.4B yen with equity of 5.2B yen, resulting in elevated debt-to-equity ratio of 2.55x and low current ratio of 52.2%, signaling liquidity and leverage concerns despite cash holdings of 5.7B yen.
Revenue increased 36.5% YoY to 1.3B yen, reflecting strong top-line momentum in the single-segment business structure. The growth appears driven by business expansion or potential scope consolidation, as the company operates under a unified segment model with no breakdown available. Cost of sales rose to 0.6B yen while maintaining gross profit margin at 53.6%, indicating effective pricing and cost management at the gross margin level. However, SG&A expenses of 1.5B yen consumed 113.3% of revenue, representing the primary drag on profitability. This resulted in operating loss of 0.8B yen, though the absolute loss amount improved slightly by 0.01B yen YoY. Operating margin of -59.7% showed substantial improvement of approximately 23 percentage points from the prior year's -82.7%, suggesting positive operating leverage is beginning to emerge, albeit from deeply negative territory. On the profit progression, ordinary loss of 0.9B yen reflected 0.1B yen of non-operating expenses, primarily commissions and minimal financial costs, widening the loss by 6.2% YoY. Net loss expanded to 0.9B yen from 0.8B yen, deteriorating 12.2% YoY, despite minimal tax impacts given the loss position. The widening gap between operating and net income stems from non-operating expenses offsetting the slight operating improvement. Comprehensive income showed minimal foreign exchange translation adjustments and securities valuation differences. This represents a revenue up/profit down pattern in absolute terms, where strong revenue growth failed to translate into profit improvement due to persistently elevated fixed cost structure and non-operating burden.
[Profitability] ROE stands at -17.3%, reflecting ongoing losses relative to equity base of 5.2B yen. Operating margin of -59.7% improved 23.0 percentage points from prior year's -82.7%, indicating improving operating leverage as revenue scales. Net margin of -66.9% remains deeply negative as net loss of 0.9B yen represents two-thirds of revenue, driven by SG&A burden exceeding revenue generation capacity. [Cash Quality] Cash and deposits of 5.7B yen provide 0.44x coverage of current liabilities of 13.1B yen, indicating adequate near-term liquidity cushion despite overall current ratio concerns. Operating cash flow of -1.8B yen represents 2.03x net income in absolute terms, with working capital deterioration, particularly accounts receivable rising 92.9% to 0.3B yen, contributing to cash consumption beyond accounting losses. [Investment Efficiency] Total asset turnover of 0.073x reflects low asset utilization, with 1.3B yen revenue generated from 18.4B yen asset base. Non-current assets of 11.6B yen include goodwill and intangible assets totaling 1.8B yen, suggesting past M&A activity. [Financial Health] Equity ratio of 28.2% indicates moderate capitalization with retained losses of -19.0B yen weighing on equity base. Current ratio of 52.2% signals liquidity pressure with current liabilities of 13.1B yen substantially exceeding current assets of 6.8B yen. Debt-to-equity ratio of 2.55x reflects elevated leverage with total liabilities of 13.2B yen against equity of 5.2B yen.
Operating cash flow of negative 1.8B yen represents 2.03x of net loss of 0.9B yen in absolute terms, indicating cash outflow exceeds accounting losses. This deterioration stems primarily from working capital movements, with accounts receivable increasing 0.15B yen (92.9% YoY) reflecting extended collection cycles, while accounts payable rose modestly by 0.01B yen (29.5% YoY), creating unfavorable net working capital impact. Depreciation and amortization of 0.01B yen provided minimal non-cash addback. Investing cash flow of negative 0.3B yen suggests limited capital expenditure given low depreciation base, with investments likely focused on intangible assets or strategic initiatives given the 0.9B yen intangible asset balance including goodwill. Financing cash flow of positive 2.4B yen provided significant capital inflow, likely through equity raises or debt financing to support operations and fund working capital needs. Free cash flow of negative 2.1B yen (operating CF minus investing CF) indicates substantial cash consumption requiring external funding. Cash position increased from prior period to 5.7B yen, absorbing the financing inflows while covering operational shortfalls. The financing CF magnitude of 2.4B yen substantially exceeds the FCF burn of 2.1B yen, enabling cash accumulation despite operational cash consumption.
Ordinary loss of 0.9B yen versus operating loss of 0.8B yen shows non-operating net expense contribution of approximately 0.1B yen, consisting primarily of commission fees and minimal financial costs. Non-operating expenses represent roughly 7% of revenue on an absolute basis, a relatively modest burden given the loss position. Interest income and foreign exchange impacts were negligible, indicating limited financial asset yields and stable currency exposure. No extraordinary items were recorded, ensuring the reported loss reflects core operating performance without one-time distortions. Operating cash flow of negative 1.8B yen compares unfavorably to net income of negative 0.9B yen, with the 2.03x ratio indicating working capital deterioration undermines cash generation. Specifically, accounts receivable growth of 92.9% substantially outpaced revenue growth of 36.5%, suggesting extended payment terms or collection challenges that convert revenue into non-cash earnings. This divergence between accrual earnings and cash realization raises quality concerns, as the receivables build-up (flagged at 85-day DSO) indicates revenue recognition may be outrunning actual cash collection. The lack of extraordinary items supports consistency in reported results, but the cash conversion weakness suggests near-term earnings quality remains constrained by working capital efficiency issues.
Liquidity pressure from low current ratio of 52.2% and short-term debt concentration represents the most immediate financial risk, with current liabilities of 13.1B yen exceeding current assets of 6.8B yen by 6.3B yen despite cash holdings of 5.7B yen, creating potential refinancing or funding needs within the operating cycle. Working capital deterioration driven by accounts receivable surge of 92.9% YoY and extended DSO of 85 days indicates growing collection risk and cash conversion challenges, potentially impairing operating cash generation and requiring additional external financing to sustain operations. Structural profitability risk from SG&A burden of 113.3% of revenue producing operating margin of -59.7% necessitates significant cost reduction or sustained revenue scale-up to reach breakeven, with current trajectory requiring multiple quarters of growth without corresponding expense increases to achieve positive operating income.
[Industry Position] (Reference - Proprietary Analysis)
The company's financial profile shows substantial divergence from typical industry standards. Operating margin of -59.7% for the current period, while improving from approximately -82.7% in the prior year, remains deeply negative compared to profitable industry norms, reflecting the company's investment phase or structural cost challenges. Net margin of -66.9% similarly indicates ongoing loss generation. Revenue growth of 36.5% YoY demonstrates strong top-line momentum that exceeds typical mature industry growth rates, suggesting either market share gains, new product success, or consolidation effects. However, this growth has not yet translated to profitability given the elevated cost structure. The lack of multi-period benchmark data for this company limits trend comparison, but the current period metrics indicate a business in transition, prioritizing growth over near-term profitability. Industry positioning appears to reflect a growth-investment phase with material execution risk tied to achieving operating leverage inflection.
※ Industry: Limited benchmark dataset available; analysis based on current period company metrics and general industry characteristics. Source: Proprietary analysis.
Strong revenue growth trajectory of 36.5% YoY demonstrates market traction and top-line momentum, with gross margin of 53.6% indicating viable unit economics at the gross profit level, suggesting the business model possesses inherent margin potential once operating leverage is achieved. Operating margin improvement of approximately 23 percentage points YoY from -82.7% to -59.7% signals emerging operating leverage as revenue scales, though absolute profitability remains distant given SG&A expenses still exceed revenue by 13.3 percentage points, requiring sustained high growth or significant cost reduction to reach breakeven. Material financial structure risks from current ratio of 52.2%, debt-to-equity of 2.55x, and negative free cash flow of 2.1B yen create near-term dependency on external financing, with recent financing CF of 2.4B yen indicating active capital raising, but sustainability hinges on demonstrating a credible path to cash flow breakeven and working capital efficiency improvement, particularly addressing the 92.9% YoY accounts receivable increase and 85-day DSO collection cycle.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.